Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 1999

View Archived Issues

Company Profile: MetaXen

Ares-Serono: Annual Report 1998

Genzyme General highlights development plans at analysts meeting

AltaRex grants Purdue Pharma an option to license two AIT products

Xoma concludes patient enrollment in Neuprex phase III pivotal trial

News from ASCO: Lutrin is safe and effective in treating locally recurrent breast cancer

Synaptic and Warner-Lambert terminate galanin receptor research collaboration

New vitronectin receptor ligands for osteoporosis, etc., synthesized by HMR and Genentech

Cytokine-suppressive antiinflammatory agents in development at SmithKline Beecham

Sanofi reports preparation and use of new cholecystokinin agonists

Phospholamban inhibitors described by Orion for use in heart failure

Disappointing results from interim analysis of experimental lupus drug

Pharmacologically useful PTPase inhibitors developed by Ontogen and Novo Nordisk

Johnson & Johnson withdraws from norastemizole collaboration

Lilly synthesizes potent and selective 5-HT4 receptor antagonists or partial agonists

Rebeccamycin analogue NSC-655649 evaluated in adult and pediatric cancer patients

Merck's new carbapenems useful against methicillin-resistant staphylococci

Synthetic histone deacetylase inhibitor with potent antitumor effects developed in Japan

Imagent improves echocardiographic evaluation of the heart in phase III trials

U.S. university research team designs potent and selective inhibitors of PGGTase-I

Pharmacokinetics of AG-2034 examined in patients; results reported at ASCO meeting

ASCO highlights: interim phase I results reported for declopramide

Enbrel shows positive results in early, active RA

Orally active antimetabolite CS-682 well tolerated in patients with refractory solid tumors

Lilly's multitargeted antifolate a protagonist at ASCO

Agouron acquired by Warner-Lambert

Further details and timetable of Rhone-Poulenc and Hoechst merger announced

Sonata now available in Denmark and Sweden

World's smallest transdermal estradiol system launched in U.S.

Two phase I trials of GBC-590 reported at ASCO meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...